The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 701–800 of 1,010
Steering the course of CAR T cell therapy with lipid nanoparticles
Khawar, M. B., Afzal, A., Si, Y., & Sun, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02630-1 · Cited by 54
Bulliard, Y., Freeborn, R. A., Uyeda, M. J., Humes, D. G., Bjordahl, R., VRIES, D. D., & Roncarolo, M. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509956 · Cited by 52
Targeting macrophages in cancer immunotherapy: Frontiers and challenges
Liu, Y., Tan, H., Dai, J., Lin, J., Zhao, K., Hu, H., & Zhong, C. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.043 · Cited by 55
“T immunotherapy approved by FDA has achieved success in the treatment of hematological malignancies [1,2].”
Cadiñanos-Garai, A., Flugel, C., Cheung, A., Jiang, E., Vaissié, A., & Abou‐El‐Enein, M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.006 · Cited by 52
“5 These outcomes are shaped by a complex interplay of tumor-intrinsic mechanisms, T cell fitness, and manufacturing variables.”
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 55
T cell immunotherapy enhanced by designer biomaterials
Dunn, Z. S., Mac, J., & Wang, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119265 · Cited by 48
Tyagarajan, S., Schmitt, D. A., Acker, C. M., & Rutjens, E. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.10.005 · Cited by 49
Marofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681984 · Cited by 48
RetractedZhang, J., Li, J., Ma, Q., Yang, H., Signorovitch, J., & Wu, E. Q. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01397-9 · Cited by 47
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 50
dos Santos, D. M. C., Rejeski, K., Winkelmann, M., Liu, L., Trinkner, P., Günther, S., Bücklein, V., Blumenberg, V., Schmidt, C., Kunz, W. G., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280189 · Cited by 46
Calabretta, E., Hamadani, M., & Carlo‐Stella, C. (2022) · Blood · doi:10.1182/blood.2021014663 · Cited by 48
Jaeger, U., Worel, N., McGuirk, J. P., Riedell, P. A., Fleury, I., Du, Y., Han, X., Pearson, D. E., Redondo, S., & Waller, E. K. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007779 · Cited by 47
Self-citationDizman, G. T., Aguado, J. M., & Fernández‐Ruiz, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2128762 · Cited by 47
Anthony-Gonda, K., Ray, A. K., Su, H., Wang, Y., Xiong, Y., Lee, D. M., Block, A., Chilunda, V., Weiselberg, J., Zemelko, L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161698 · Cited by 47
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Qin, Y., Huo, M., Liu, X., & Li, S. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368749 · Cited by 51
Mechanisms and management of CAR T toxicity
Ferreri, C. J., & Bhutani, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1396490 · Cited by 56
Shen, Z., Che, X., Zhang, K., Bai, Y., & Deng, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.014 · Cited by 49
Novel and emerging therapies for B cell lymphoma
Ayyappan, S. R., & Maddocks, K. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0752-3 · Cited by 52
Zhou, X., Rasche, L., Kortüm, K. M., Danhof, S., Hudecek, M., & Einsele, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620312 · Cited by 49
Vasileiou, S., Lulla, P., Tzannou, I., Watanabe, A., Kuvalekar, M., Callejas, W. L., Bilgi, M., Wang, T., Wu, M., Kamble, R. T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02224 · Cited by 47
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells
Dayagi, T. W., Sherman, G., Bielorai, B., Adam, E., Besser, M. J., Shimoni, A., Nagler, A., Toren, A., Jacoby, E., & Avigdor, A. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1881506 · Cited by 47
Ayuk, F. A., Berger, C., Badbaran, A., Zabelina, T., Sonntag, T., Riecken, K., Geffken, M., Wichmann, D., Frenzel, C., Thayssen, G., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003959 · Cited by 47
Bachanova, V., Perales, M.-A., & Abramson, J. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2019.100640 · Cited by 46
Radek, C., Bernadin, O., Drechsel, K., Cordes, N., Pfeifer, R., Sträßer, P., Mormin, M., Gutiérrez-Guerrero, A., Cosset, F., Kaiser, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.157 · Cited by 46
Textor, A., Grunewald, L., Anders, K., Klaus, A., Schwiebert, S., Winkler, A., Stecklum, M., Rolff, J., Henssen, A. G., Höpken, U. E., et al. (2021) · Cancers · doi:10.3390/cancers13051050 · Cited by 47
Liu, M., Deng, H., Mu, J., Li, Q., Pu, Y., Jiang, Y., Deng, Q., & Qian, Z. (2021) · Cancer Science · doi:10.1111/cas.14915 · Cited by 45
Keating, S. J., Gu, T., Jun, M. P., & McBride, A. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.021 · Cited by 46
Harrysson, S., Eloranta, S., Ekberg, S., Enblad, G., El‐Galaly, T. C., Sander, B., Sonnevi, K., Andersson, P., Jerkeman, M., & Smedby, K. E. E. (2022) · British Journal of Haematology · doi:10.1111/bjh.18197 · Cited by 46
Brudno, J. N., Natrakul, D. A., Lam, N., Dulau‐Florea, A., Yuan, C. M., & Kochenderfer, J. N. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056172 · Cited by 46
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy
Guo, S., Lei, W., Jin, X., Liu, H., Wang, J. Q., Deng, W., & Qian, W. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012202 · Cited by 46
“6 Among them, approximately one-third of patients with LBCL relapsed, with CD19 loss mediated by mutations and splice variants of the CD19 gene as well as switching of tumor lineage, 6 suggesting that there is a need to validate novel immunotherapies directed to alternative antigen.”
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Canedo, G. D. O., Roddie, C., & Amrolia, P. J. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013586 · Cited by 47
Complex neural-immune interactions shape glioma immunotherapy
Song, K.-W., Lim, M. K., & Monje, M. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.017 · Cited by 50
Ansell, S. M., & Lin, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129206 · Cited by 48
T lymphocyte-targeted immune checkpoint modulation in glioma
Kelly, W., Giles, A. J., & Gilbert, M. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000379 · Cited by 47
Chimeric antigen receptor–T cells with cytokine neutralizing capacity
Tan, A. H. J., Vinanica, N., & Campana, D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001287 · Cited by 45
Pabst, T., Joncourt, R., Shumilov, E., Heini, A. D., Wiedemann, G., Legros, M., Seipel, K., Schild, C., Jalowiec, K. A., Taleghani, B. M., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.07.003 · Cited by 50
Current Treatment Options in CLL
Bewarder, M., Stilgenbauer, S., Thurner, L., & Kaddu‐Mulindwa, D. (2021) · Cancers · doi:10.3390/cancers13102468 · Cited by 48
Mechanisms of resistance to CAR T cell therapies
Singh, N., Orlando, E. J., Xu, J., Xu, J., Binder, Z. A., Collins, M. A., O’Rourke, D. M., & Melenhorst, J. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.002 · Cited by 48
Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
Zhao, S., Wang, C., Lu, P., Lou, Y., Liu, H., Wang, T., Yang, S., Bao, Z., Han, L. G., Liang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003176 · Cited by 46
Zaki, A. A., Feng, L., Watson, G., Ahmed, S., Mistry, H. E., Nastoupil, L. J., Hawkins, M., Nair, R. K., Iyer, S. P., Lee, H. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006715 · Cited by 45
Self-citationDevelopment of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
Moon, D., Tae, N., Park, Y., Lee, S., & Kim, D. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e4 · Cited by 48
Shi, B., Li, D., Yao, W., Wang, W., Jiang, J., Wang, R., Yan, F., Liu, H., Zhang, H., & Ye, J. (2022) · Biomaterials Science · doi:10.1039/d1bm01982a · Cited by 45
Márquez‐Algaba, E., Iacoboni, G., Pernas, B., Esperalba, J., Arcos, I. L., Navarro, V., Monforte, A., Beas, F., Albasanz‐Puig, A., Carpio, C. D. C., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.09.007 · Cited by 45
Karschnia, P., Arrillaga‐Romany, I., Eichler, A. F., Forst, D. A., Gerstner, E. R., Jordan, J. T., Ly, I., Plotkin, S. R., Wang, N., Martinez‐Lage, M., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad118 · Cited by 45
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Faramand, R. G., Lee, S. B., Jain, M. D., Cao, B., Wang, X., Rejeski, K., Subklewe, M. S., Fahrmann, J. F., Saini, N. Y., Hanash, S., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0056 · Cited by 46
Fischer‐Riepe, L., Kailayangiri, S., Zimmermann, K., Pfeifer, R., Aigner, M., Altvater, B., Kretschmann, S., Völkl, S., Hartley, J., Dreger, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3157 · Cited by 45
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial
Maziarz, R. T., Schuster, S. J., Romanov, V. V., Rusch, E. S., Li, J., Signorovitch, J., Maloney, D. G., & Locke, F. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001305 · Cited by 45
Self-citationCao, J., Wang, H., Gao, W., You, J., Wu, L.-H., & Wang, Z.-X. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.015 · Cited by 45
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma
Englisch, A., Altvater, B., Kailayangiri, S., Hartmann, W., & Rössig, C. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28313 · Cited by 48
Carbonneau, S., Sharma, S. P., Peng, L., Rajan, V., Hainzl, D., Hénault, M., Yang, C., Hale, J. A., Shulok, J. R., Tallarico, J. A., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.012 · Cited by 47
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Kasamon, Y. L., Price, L., Okusanya, Ó. O., Richardson, N. C., Li, R., Ma, L., Wu, Y., Theoret, M. R., Pazdur, R., & Gormley, N. J. (2021) · The Oncologist · doi:10.1002/onco.13859 · Cited by 46
CAR T-cell therapy and critical care
Messmer, A. S., Que, Y., Schankin, C. J., Banz, Y., Bacher, U., Novak, U., & Pabst, T. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01948-2 · Cited by 49
Targeting the Microenvironment for Treating Multiple Myeloma
Neumeister, P., Schulz, E., Pansy, K., Szmyra, M., & Deutsch, A. J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147627 · Cited by 43
Beyar‐Katz, O., Kikozashvili, N., On, Y. B., Amit, O., Perry, C., Avivi, I. M., Gold, R., Herishanu, Y., Benyamini, N., Duek, A., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13712 · Cited by 44
CAR T-Cell Therapy in the Older Person: Indications and Risks
Shouse, G., Danilov, A. V., & Artz, A. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01272-6 · Cited by 44
Keshavarz, A., Salehi, A., Khosravi, S., Shariati, Y., Nasrabadi, N., Kahrizi, M. S., Maghsoodi, S., Mardi, A., Azizi, R., Jamali, S., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03163-w · Cited by 47
Major, A., Yu, J., Shukla, N., Che, Y., Karrison, T. G., Treitman, R., Kamdar, M. K., Haverkos, B. M., Godfrey, J. K., Babcook, M. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010016 · Cited by 43
Self-citationEpperla, N., Kumar, A., Abutalib, S. A., Awan, F. T., Chen, Y., Gopal, A. K., Chakrabarty, J. H., Kekre, N. K., Lee, C. J., Lekakis, L. J., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.06.012 · Cited by 44
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 44
S, K. D. S., Joga, R., Srivastava, S., Nagpal, K., Dhamija, I., Grover, P., & Kumar, S. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114361 · Cited by 44
Strati, P., Ahmed, M. A., Fowler, N. H., Nastoupil, L. J., Samaniego, F., Fayad, L., Hagemeister, F. B., Romaguera, J. E., Rodriguez, M. A., Wang, M. L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.230649 · Cited by 44
Self-citationViardot, A., Locatelli, F., Stieglmaier, J., Zaman, F., & Jabbour, E. J. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04221-0 · Cited by 45
Reagan, P. M., & Neelapu, S. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01616 · Cited by 44
Martín‐Rojas, R. M., Gómez-Centurión, I. A., Bailén, R., Bastos‐Oreiro, M., Diaz-Crespo, F. J., Carbonell, D., Correa‐Rocha, R., Pion, M., Muñoz, C., Sancho, M., et al. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5209 · Cited by 46
Role of bridging therapy during chimeric antigen receptor T cell therapy
Bhaskar, S., Dholaria, B., Sengsayadeth, S. M., Savani, B. N., & Oluwole, O. O. (2021) · eJHaem · doi:10.1002/jha2.335 · Cited by 42
Artificial Intelligence in Lymphoma PET Imaging
Hasani, N., Paravastu, S. S., Farhadi, F., Yousefirizi, F., Morris, M. A., Rahmim, A., Roschewski, M. J., Summers, R. M., & Saboury, B. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.09.006 · Cited by 45
NK Cell-Based Immunotherapy in Colorectal Cancer
Chiesa, M. D., Setti, C., Giordano, C., Obino, V., Greppi, M., Pesce, S., Marcenaro, E., Rutigliani, M., Provinciali, N., Paleari, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10071033 · Cited by 44
Kanate, A., Majhail, N., DeFilipp, Z. M., Dhakal, B., Dholaria, B. R., Hamilton, B., Herrera, A., Inamoto, Y., Jain, T., Perales, M., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.07.002 · Cited by 46
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 46
Role of the gut microbiota in tumorigenesis and treatment
Liu, Q., Yang, Y., Pan, M., Yang, F., Yu, Y., & Qian, Z. (2024) · Theranostics · doi:10.7150/thno.91700 · Cited by 46
Altered cancer metabolism and implications for next-generation CAR T-cell therapies
Ramapriyan, R., Vykunta, V. S., Vandecandelaere, G., Richardson, L. G., Sun, J. M., Curry, W. T., & Choi, B. D. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108667 · Cited by 48
IL-4 drives exhaustion of CD8+ CART cells
Stewart, C. M., Siegler, E. L., Sakemura, R. L., Cox, M. J., Huynh, T., Kimball, B. L., Mai, L., Can, İ., Roman, C. M., Yun, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51978-3 · Cited by 43
“While CART cell therapy results in impressive overall response rates over 70%, durable response rates remain limited to 30 – 40%, and most patients relapse within the fi rst year of therapy 2 – 4 .”
González-Barca, E. M., Boumendil, A., Blaise, D., Trněný, M., Masszi, T., Finel, H., Michieli, M., Bittenbring, J. T., Gritti, G., Snowden, J. A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0650-x · Cited by 43
Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome
Stahl, K., Schmidt, B. M. W., Hoeper, M. M., Skripuletz, T., Möhn, N., Beutel, G., Eder, M., Welte, T., Ganser, A., Falk, C. S., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.02.010 · Cited by 45
Leick, M. B., Maus, M. V., & Frigault, M. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.022 · Cited by 43
Korell, F., Schubert, M., Sauer, T., Schmitt, A., Derigs, P., Weber, T. F., Schnitzler, P., Müller‐Tidow, C., Dreger, P., & Schmitt, M. W. (2021) · Cancers · doi:10.3390/cancers13071684 · Cited by 43
Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
Dong, Y., Wan, Z., Gao, X., Yang, G., & Liu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609762 · Cited by 45
Mueller‐Schoell, A., Puebla‐Osorio, N., Michelet, R., Green, M. R., Künkele, A., Huisinga, W., Strati, P., Chasen, B., Neelapu, S. S., Yee, C., et al. (2021) · Cancers · doi:10.3390/cancers13112782 · Cited by 44
CAR T-Cell Therapy: An Update for Radiologists
Yoon, J. G., Smith, D. A., Tirumani, S. H., Caimi, P. F., & Ramaiya, N. H. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26091 · Cited by 43
Northend, M., Wilson, W., Osborne, W., Fox, C. P., Davies, A. J., El‐Sharkawi, D., Phillips, E. H., Sim, H. W., Sadullah, S., Shah, N., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005953 · Cited by 43
Pampusch, M. S., Abdelaal, H. M., Cartwright, E. K., Molden, J. S., Davey, B. C., Sauve, J. D., Sevcik, E. N., Rendahl, A., Rakasz, E. G., Connick, E., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1009831 · Cited by 43
Breen, W. G., Hathcock, M. A., Young, J. R., Kowalchuk, R. O., Bansal, R., Khurana, A., Bennani, N. N., Paludo, J., Villasboas, J. C., Wang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01256-w · Cited by 42
Fertility and CAR T-cells: Current practice and future directions
Ligon, J. A., Fry, A., Maher, J. Y., Foley, T., Silbert, S. K., Yates, B., Gomez‐Lobo, V., Wiener, L. S., & Shah, N. N. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.002 · Cited by 42
Sharun, K., Tiwari, R., Yatoo, M. I., Natesan, S., Megawati, D., Singh, K. P., Michalak, I., & Dhama, K. (2022) · Narra J · doi:10.52225/narra.v2i3.92 · Cited by 42
CAR T cells: engineered immune cells to treat brain cancers and beyond
Huang, Z., Dewanjee, S., Chakraborty, P., Jha, N. K., Dey, A., Gangopadhyay, M., Chen, X.-Y., Wang, J., & Jha, S. K. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01712-8 · Cited by 46
Nasiri, F., Kozani, P. S., & Rahbarizadeh, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063838 · Cited by 42
Johnson, P. C., Dhawale, T. M., Newcomb, R. A., Amonoo, H. L., Lavoie, M. W., Vaughn, D., Karpinski, K., & El-Jawahri, A. R. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009117 · Cited by 42
Lee, S. Y., Lee, D. H., Sun, W., Cervantes-Contreras, F., Basom, R., Wu, F., Liu, S., Rai, R., Mirzaei, H. R., O’Steen, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007803 · Cited by 42
Lei, W., Zhao, A., Liu, H., Yang, C., Cheng, W., Guo, S., Chen, Z., Guo, Q., Li, L., Zhao, M., et al. (2024) · Cell Discovery · doi:10.1038/s41421-023-00625-0 · Cited by 46
Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
Dalle, I. A., Duléry, R., Moukalled, N. M., Ricard, L., Stocker, N., Cheikh, J. E., Mohty, M., & Bazarbachi, A. A. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00989-w · Cited by 42
Sam, J., Höfer, T., Kuettel, C., Claus, C., Thom, J. T., Herter, S., Georges, G. J., Korfi, K., Lechmann, M., Eigenmann, M. J., et al. (2024) · Blood · doi:10.1182/blood.2023023381 · Cited by 42
Shumilov, E., Scholz, J. K., Seib, M., Mazzeo, P., Wurm‐Kuczera, R., Vučinić, V., Holtick, U., Boyadzhiev, H., Melchardt, T., Hölscher, A. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015719 · Cited by 45
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong, E. A., Levine, B. L., Grupp, S. A., Suhoski, M. M., Siegel, D. L., Maude, S. L., Gladney, W. L., Frey, N. V., Porter, D. L., Hwang, W., et al. (2019) · Blood · doi:10.1182/blood.2019002258 · Cited by 42
Self-citationMechanisms of failure of chimeric antigen receptor T-cell therapy
Li, X., & Chen, W. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000548 · Cited by 41
Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
Munter, S. D., Parys, A. V., Bral, L., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Billiet, L., Weening, K., Verhee, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030883 · Cited by 46
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 42
The promise and perils of immunotherapy
Lesch, S., & Gill, S. I. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004453c · Cited by 44
Moreno-Cortes, E. F., Forero-Forero, J. V., Lengerke-Diaz, P. A., & Castro, J. E. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103239 · Cited by 41
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity
He, Y., Vlaming, M., van Meerten, T., & Bremer, E. (2022) · Cancers · doi:10.3390/cancers14020299 · Cited by 40
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
